JP2006519818A5 - - Google Patents

Download PDF

Info

Publication number
JP2006519818A5
JP2006519818A5 JP2006505451A JP2006505451A JP2006519818A5 JP 2006519818 A5 JP2006519818 A5 JP 2006519818A5 JP 2006505451 A JP2006505451 A JP 2006505451A JP 2006505451 A JP2006505451 A JP 2006505451A JP 2006519818 A5 JP2006519818 A5 JP 2006519818A5
Authority
JP
Japan
Prior art keywords
cyclopropylmethoxy
dichloropyridine
amino
anion
activated derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006505451A
Other languages
English (en)
Japanese (ja)
Other versions
JP4742026B2 (ja
JP2006519818A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2004/050272 external-priority patent/WO2004080967A1/en
Publication of JP2006519818A publication Critical patent/JP2006519818A/ja
Publication of JP2006519818A5 publication Critical patent/JP2006519818A5/ja
Application granted granted Critical
Publication of JP4742026B2 publication Critical patent/JP4742026B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006505451A 2003-03-10 2004-03-08 ロフルミラストの新規の製造方法 Expired - Fee Related JP4742026B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03005245.0 2003-03-10
EP03005245 2003-03-10
PCT/EP2004/050272 WO2004080967A1 (en) 2003-03-10 2004-03-08 Novel process for the preparation of roflumilast

Publications (3)

Publication Number Publication Date
JP2006519818A JP2006519818A (ja) 2006-08-31
JP2006519818A5 true JP2006519818A5 (enExample) 2007-04-19
JP4742026B2 JP4742026B2 (ja) 2011-08-10

Family

ID=32981730

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006505451A Expired - Fee Related JP4742026B2 (ja) 2003-03-10 2004-03-08 ロフルミラストの新規の製造方法

Country Status (29)

Country Link
US (5) US7470791B2 (enExample)
EP (1) EP1606261B1 (enExample)
JP (1) JP4742026B2 (enExample)
KR (1) KR101179012B1 (enExample)
CN (1) CN100471840C (enExample)
AR (1) AR043531A1 (enExample)
AT (1) ATE447555T1 (enExample)
AU (1) AU2004220357B2 (enExample)
BR (1) BRPI0406427B8 (enExample)
CA (1) CA2503290C (enExample)
CY (1) CY1109580T1 (enExample)
DE (1) DE602004023921D1 (enExample)
DK (1) DK1606261T3 (enExample)
EA (1) EA009985B1 (enExample)
ES (1) ES2335498T3 (enExample)
HR (1) HRP20050399B1 (enExample)
IL (1) IL168170A (enExample)
IS (1) IS2723B (enExample)
ME (1) ME00524B (enExample)
MX (1) MXPA04008070A (enExample)
NO (1) NO329301B1 (enExample)
NZ (1) NZ539542A (enExample)
PL (1) PL1606261T3 (enExample)
PT (1) PT1606261E (enExample)
RS (2) RS52908B (enExample)
SI (1) SI1606261T1 (enExample)
TW (1) TWI340741B (enExample)
WO (1) WO2004080967A1 (enExample)
ZA (1) ZA200503191B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
KR101179012B1 (ko) 2003-03-10 2012-09-03 니코메드 게엠베하 로플루미라스트 신규한 제조 방법
US20070254928A1 (en) * 2004-05-10 2007-11-01 Altana Pharma Ag Use of Roflumilast for the Prophylaxis or Treatment of Emphysema
EP1861074B1 (en) 2005-03-16 2013-04-24 Takeda GmbH Taste masked dosage form containing roflumilast
CN102311382B (zh) * 2010-06-29 2014-05-21 大道隆达（北京）医药科技发展有限公司 罗氟司特的晶态及其制备方法
CN102617457A (zh) * 2011-01-28 2012-08-01 天津药物研究院 一种制备罗氟司特的新方法
WO2012147098A2 (en) * 2011-04-28 2012-11-01 Glenmark Generics Limited Novel process for the preparation of 3-(cyclopropylmethoxy)-n-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy) benzamide
CN102775345A (zh) * 2011-05-13 2012-11-14 上海特化医药科技有限公司 制备罗氟司特的方法及中间体
CN102336703B (zh) * 2011-07-20 2013-09-25 华润赛科药业有限责任公司 一种制备罗氟司特的方法
CN102351787B (zh) * 2011-08-18 2014-08-13 天津市汉康医药生物技术有限公司 高生物利用度的罗氟司特化合物
CN103012255B (zh) * 2011-09-21 2014-06-11 天津康鸿医药科技发展有限公司 罗氟司特晶型化合物、其制备方法、组合物及应用
CN102336704B (zh) * 2011-10-19 2013-04-17 丁克 一种制备罗氟司特的方法
CN102336705B (zh) * 2011-10-28 2013-03-27 成都苑东药业有限公司 一种制备n-(3,5-二氯吡啶-4-基)-3-环丙基甲氧基-4-二氟甲氧基苯甲酰胺的方法
CN102603623A (zh) * 2011-12-26 2012-07-25 北京赛林泰医药技术有限公司 制备高纯度罗氟司特的方法
CN102617340B (zh) * 2012-03-05 2014-03-26 山西仟源制药股份有限公司 制备3-环丙基甲氧基-4-二氟甲氧基苯甲酸的方法
WO2013131255A1 (en) 2012-03-07 2013-09-12 Scinopharm (Changshu) Pharmaceutical, Ltd. Preparation method of roflumilast
CN104245672B (zh) * 2012-03-07 2016-05-18 神隆医药（常熟）有限公司 制备罗氟司特的方法
WO2014012954A1 (en) 2012-07-18 2014-01-23 Takeda Gmbh Treatment of partly controlled or uncontrolled severe asthma
CN103570610B (zh) * 2012-07-18 2017-08-11 重庆华邦制药有限公司 一种罗氟司特微粒的制备方法
WO2014060464A1 (en) 2012-10-17 2014-04-24 Interquim, S.A. Process for preparing roflumilast
CN103319333B (zh) * 2013-07-15 2014-12-10 天津南开允公医药科技有限公司 一种制备3-环丙基甲氧基-4-二氟甲氧基苯甲酰氯化合物的方法
US10357486B2 (en) 2013-08-16 2019-07-23 Universiteit Maastricht Treatment of cognitive impairment with PDE4 inhibitor
AU2014307802A1 (en) * 2013-08-16 2016-03-10 Universiteit Maastricht Treatment of cognitive impairment with combination therapy
CN103536582A (zh) * 2013-10-12 2014-01-29 云南龙海天然植物药业有限公司 罗氟司特干粉吸入剂
CN104892500A (zh) * 2015-05-18 2015-09-09 武汉利宝瑞医药科技有限公司 罗氟司特的合成工艺
WO2018003867A1 (ja) * 2016-07-01 2018-01-04 久光製薬株式会社 Ｎ－（３，５－ジクロロピリド－４－イル）－ｎ－メチル－３－シクロプロピルメトキシ－４－ジフルオロメトキシベンズアミドの製造方法
US11129818B2 (en) 2017-06-07 2021-09-28 Arcutis Biotherapeutics, Inc. Topical roflumilast formulation having improved delivery and plasma half life
US12042487B2 (en) 2018-11-16 2024-07-23 Arcutis Biotherapeutics, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US12011437B1 (en) 2017-06-07 2024-06-18 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US20200155524A1 (en) 2018-11-16 2020-05-21 Arcutis, Inc. Method for reducing side effects from administration of phosphodiesterase-4 inhibitors
US20210161870A1 (en) 2017-06-07 2021-06-03 Arcutis Biotherapeutics, Inc. Roflumilast formulations with an improved pharmacokinetic profile
US9895359B1 (en) 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
US11534493B2 (en) 2017-09-22 2022-12-27 Arcutis Biotherapeutics, Inc. Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents
WO2019236374A2 (en) 2018-06-04 2019-12-12 Arcutis, Inc. Method and formulation for improving roflumilast skin penetration lag time
CA3162675C (en) 2020-12-04 2023-09-26 Saori Kato Topical roflumilast formulation having antifungal properties
MA60224B1 (fr) 2021-07-09 2024-06-28 Astrazeneca Pharmaceuticals Lp Compositions, méthodes et systèmes pour l'administration d'un médicament en aérosol
CN118414148A (zh) 2021-12-20 2024-07-30 阿斯利康(瑞典)有限公司 用于气溶胶药物递送的组合物、方法和系统
AU2022429340A1 (en) 2021-12-28 2024-08-01 Arcutis Biotherapeutics, Inc. Topical roflumilast aerosol foams
KR20250057103A (ko) 2022-09-15 2025-04-28 아큐티스 바이오테라퓨틱스, 인크. 로플루밀라스트 및 많은 양의 약물을 용해시킬 수 있는 용매의 약학 조성물

Family Cites Families (154)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065142A (en) 1958-07-30 1962-11-20 Armour Pharma Gastric resistant medicinal preparation
US4006227A (en) 1973-11-15 1977-02-01 Gallegos Alfred J Compositions and methods for fertility control
US4024240A (en) 1975-07-18 1977-05-17 Eli Lilly And Company Antibiotic A-32390 compositions
US4343804A (en) 1979-03-26 1982-08-10 A. H. Robins Company, Inc. 4-Amino-3-quinolinecarboxylic acids and esters-antisecretory anti-ulcer compounds
NZ196700A (en) 1980-04-18 1983-04-12 Smith & Nephew Ass Anti-inflammatory compositions containing 5-benzoyl-1-methylpyrrole-2-acetic acid derivatives
DE3269604D1 (en) 1981-06-26 1986-04-10 Schering Corp Novel imidazo(1,2-a)pyridines and pyrazines, processes for their preparation and pharmaceutical compositions containing them
US4464372A (en) 1982-08-16 1984-08-07 Schering Corporation Imidazo[1,2-b]pyridazines
GB8305245D0 (en) 1983-02-25 1983-03-30 Fujisawa Pharmaceutical Co Imidazo-heterocyclic compounds
GB8307865D0 (en) 1983-03-22 1983-04-27 Fujisawa Pharmaceutical Co Benzimidazole derivatives
GB8415540D0 (en) 1984-06-18 1984-07-25 Fujisawa Pharmaceutical Co Imidazoisoquinoline compounds
US4725601A (en) 1985-06-04 1988-02-16 Fujisawa Pharmaceutical Co., Ltd. Certain imidazo[1,2-a]pyridines useful in the treatment of ulcers
JPS625966A (ja) 1985-07-03 1987-01-12 Nippon Shinyaku Co Ltd ベンズイミダゾ−ル誘導体
EP0228006A1 (en) 1985-12-16 1987-07-08 Fujisawa Pharmaceutical Co., Ltd. Imidazopyridine compounds and processes for preparation thereof
US4753945A (en) 1986-02-19 1988-06-28 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with phosphodiesterase inhibitors
US5286494A (en) 1986-07-02 1994-02-15 Schering Aktiengesellschaft Medicinal agents with sustained action
GB8621425D0 (en) 1986-09-05 1986-10-15 Smith Kline French Lab Compounds
US4791117A (en) 1986-09-22 1988-12-13 Ortho Pharmaceutical Corporation 2- or 3-aryl substituted imidazo[1,2-a]pyridines and their use as calcium channel blockers
US4833149A (en) 1986-09-22 1989-05-23 Ortho Pharmaceutical Corporation 2- or 3-aryl substituted imidazo[1,2-a]pyridines
EP0264883A3 (en) 1986-10-21 1990-04-04 Banyu Pharmaceutical Co., Ltd. Substituted pyridine derivatives
US4831041A (en) 1986-11-26 1989-05-16 Fujisawa Pharmaceutical Co., Ltd. Imidazopyridine compounds and processes for preparation thereof
CA1327796C (en) 1987-07-16 1994-03-15 Jorg Senn-Bilfinger Diazoles
GB8717644D0 (en) 1987-07-24 1987-09-03 Smithkline Beckman Intercredit Compounds
GB8722488D0 (en) 1987-09-24 1987-10-28 Fujisawa Pharmaceutical Co Imidazopyridine compound
GB8804444D0 (en) 1988-02-25 1988-03-23 Smithkline Beckman Intercredit Compounds
US4900775A (en) 1988-02-29 1990-02-13 Gaf Chemicals Corporation Solubilization of complexes of water-insoluble organic compounds by aqueous solutions of polyvinylpyrrolidone
US5011843A (en) 1988-05-31 1991-04-30 Iolab Corporation Treatment of glaucoma using phosphodiesterase inhibitors
CA2011086A1 (en) 1989-03-17 1990-09-17 Karl-Heinz Geiss 2-alkyl-4-arylmethylaminoquinolines, the use thereof and drugs prepared therefrom
GB8908229D0 (en) 1989-04-12 1989-05-24 Smithkline Beckman Intercredit Compounds
DE3917233A1 (de) 1989-05-26 1990-11-29 Basf Ag 8-substituierte 4-(heterocyclylmethylamino)-chinoline, ihre verwendung und daraus hergestellte arzneimittel
DE3917232A1 (de) 1989-05-26 1990-11-29 Basf Ag 4-arylmethamino-2,3-dialkyl-chinoline, ihre verwendung und daraus hergestellte arzneimittel
DE3943385A1 (de) 1989-12-27 1991-07-04 Schering Ag Mittel zur transdermalen applikation enthaltend rolipram
FR2657257B1 (fr) 1990-01-19 1994-09-02 Rhone Poulenc Sante Procede de preparation de medicaments sous forme de perles.
DE69128682T2 (de) 1990-03-28 1998-06-04 Otsuka Pharma Co Ltd Chinolinderivat, antiulcus-mittel das dieses derivat enthält und darstellung dieses derivates
US5041442A (en) 1990-07-31 1991-08-20 Syntex (U.S.A.) Inc. Pyrrolo(1,2-a)pyrazines as inhibitors of gastric acid secretion
US5698711A (en) 1991-01-28 1997-12-16 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
SE9100920D0 (sv) 1991-03-27 1991-03-27 Astra Ab New active compounds
JP2948317B2 (ja) 1991-05-28 1999-09-13 マクニール―ピーピーシー・インコーポレーテツド 噛める薬物投与用組成物
JP3108483B2 (ja) 1991-09-30 2000-11-13 日清製粉株式会社 インドール誘導体およびこれを有効成分とする抗潰瘍薬
JP3038064B2 (ja) 1991-10-07 2000-05-08 日清製粉株式会社 インドール誘導体およびこれを有効成分とする抗潰瘍薬
US5534515A (en) 1991-10-25 1996-07-09 Byk Gulden Lomberg Chemische Fabrik Gmbh Pyrrolopyridazines having gastrointestinal protective effects
US5262171A (en) 1991-11-25 1993-11-16 Isp Investments Inc. Pharmaceutical tablet with PVP having enhanced drug dissolution rate
CA2124821C (en) 1991-12-18 2003-10-07 Isaac Ghebre-Sellassie Novel solid pharmaceutical dispersions
GB9201693D0 (en) 1992-01-27 1992-03-11 Smithkline Beecham Intercredit Compounds
GB9212693D0 (en) 1992-06-15 1992-07-29 Celltech Ltd Chemical compounds
CA2114114C (en) * 1992-06-15 2005-05-03 Nigel Robert Arnold Beeley Trisubstituted phenyl derivatives as selective phosphodiesterase iv inhibitors
IL106517A0 (en) 1992-07-28 1994-08-26 Rhone Poulenc Rorer Ltd Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic or heteroatom containing linking group
US5891904A (en) 1992-09-14 1999-04-06 Wolf-Georg Forssmann Use of inhibitors of phosphodiesterase IV
JP3284622B2 (ja) 1992-10-23 2002-05-20 ソニー株式会社 ディスク装置
US5429824A (en) 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
KR0144833B1 (ko) 1992-12-28 1998-07-15 김태훈 신규의 퀴나졸린 유도체 및 그의 제조방법
IL108520A (en) 1993-02-15 1997-09-30 Byk Gulden Lomberg Chem Fab 2, 3, 8-TRISUBSTITUTED IMIDAZO £1, 2-a| PYRIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
EP0695303B1 (de) 1993-04-22 2001-11-28 Byk Gulden Lomberg Chemische Fabrik GmbH Pyridiniumsalze und ihre verwendung zur bekämpfung von helicobacter-bakterien
US5712298A (en) 1993-07-02 1998-01-27 Byk Gulden Lomberg Chemische Fabrik Gmbh Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors
JP3284686B2 (ja) 1993-08-30 2002-05-20 株式会社明電舎 ブレーキダイナモメータシステムのブレーキトルク制御方式
UA48122C2 (uk) 1993-10-11 2002-08-15 Бік Гульден Ломберг Хеміше Фабрік Гмбх АЛКОКСІАЛКІЛКАРБАМАТИ ІМІДАЗО[1,2-а]ПІРИДИНІВ, СПОСІБ ЇХ ОДЕРЖАННЯ ТА ЛІКАРСЬКИЙ ЗАСІБ НА ЇХ ОСНОВІ
JPH10505333A (ja) 1994-07-28 1998-05-26 ビイク グルデン ロンベルク ヒェーミッシェ ファブリーク ゲゼルシャフト ミット ベシュレンクテル ハフツング イミダゾピリジン−アゾリジノン
JP3031280B2 (ja) 1994-08-19 2000-04-10 東陶機器株式会社 便器洗浄装置
GB9514473D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
SE512835C2 (sv) 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
US6114537A (en) 1996-02-26 2000-09-05 Apotex Inc. Process for scavenging thiols
US5677302A (en) 1996-02-26 1997-10-14 Apotex Inc. Thiadiazole compounds useful as proton pump inhibitors
FR2746800B1 (fr) 1996-03-29 1998-06-05 Jouveinal Inst Rech Diazepino-indoles inhibiteurs de phosphodiesterases 4
US5972381A (en) 1996-06-28 1999-10-26 Schering Corporation Solid solution of an antifungal agent with enhanced bioavailability
US5762953A (en) 1996-08-22 1998-06-09 Theratech, Inc. Transdermal propentofylline compositions for the treatment of Alzheimers disease
TR199901772T2 (enExample) 1997-02-17 1999-09-21 Byk Gulden Lomberg Chemische Fabrik Gmbh
SE9700661D0 (sv) 1997-02-25 1997-02-25 Astra Ab New compounds
US6624181B1 (en) 1997-02-28 2003-09-23 Altana Pharma Ag Synergistic combination
ATE400577T1 (de) 1997-05-28 2008-07-15 Nycomed Gmbh Anellierte dihydropyrane
IT1294748B1 (it) 1997-09-17 1999-04-12 Permatec Tech Ag Formulazione per un dispositivo transdermico
HUP0100065A2 (hu) 1997-12-08 2001-08-28 Byk Gulden Lomberg Chemische Fabrik Gmbh. Savérzékeny vegyületet tartalmazó új kúp gyógyszerforma
SE9801526D0 (sv) 1998-04-29 1998-04-29 Astra Ab New compounds
HK1039072A1 (zh) 1998-05-07 2002-04-12 科里克萨有限公司 佐剂组合物及其使用方法
EP1085846A2 (en) 1998-06-08 2001-03-28 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
SE9802794D0 (sv) 1998-08-21 1998-08-21 Astra Ab New compounds
SE9802793D0 (sv) 1998-08-21 1998-08-21 Astra Ab New compounds
NZ527232A (en) 1998-08-26 2005-03-24 Smithkline Beecham Corp A composition contaning a PDE 4 inhibitor and a beta adrenergic bronchodilator useful for treating pulmonary diseases
US6436953B1 (en) 1998-09-23 2002-08-20 Byk Gulden Lomberg Chemische Fabrik Gmbh Tetrahydropyridoethers
KR20010075287A (ko) 1998-09-29 2001-08-09 후지야마 아키라 피리도피라진 화합물의 신규한 염 및 그의 결정
WO2000020033A1 (en) 1998-10-05 2000-04-13 Eisai Co., Ltd. Tablets immediately disintegrating in the oral cavity
US20020006418A1 (en) 1998-10-13 2002-01-17 John Kung Composition to enhance permeation of topical skin agents
US6384048B1 (en) 1998-11-03 2002-05-07 Byk Gulden Lomberg Chemische Fabrik Gmbh Imidazonaphthyridines
US6417190B1 (en) 1998-12-17 2002-07-09 Boehringer Ingelheim Pharma Kg Tricyclic nitrogen heterocycles as PDE IV inhibitors
DZ3019A1 (fr) 1999-03-01 2005-05-20 Smithkline Beecham Corp Utilisation d'un inhibiteur de pde4 dans la préparation d'un médicament contre la copd.
US6270807B1 (en) 1999-03-02 2001-08-07 L. Perrigo Company Taste-masked pharmaceutical composition
ES2231162T3 (es) 1999-03-10 2005-05-16 Altana Pharma Ag 3-ciclopropilmetoxi-4-difluorometoxi-n-(33,5-dicloropirid-4 il)benzamida en el tratamiento de la esclerosis multiple.
CN1126468C (zh) 1999-04-08 2003-11-05 王力田 一种黑玉米秸秆饮料及其制备方法
DK1173439T3 (da) 1999-04-17 2003-09-08 Altana Pharma Ag Halogenalkoxy-imidazonaphthyridiner
KR100328972B1 (ko) 1999-04-23 2002-03-20 서경배 피부 유용 활성성분을 함유한 화장료 또는 피부도포용 의약품 조성물의 제조방법 및 이러한 방법에 의해 제조된 화장료 또는 피부도포용 의약품 조성물
ES2228512T3 (es) 1999-05-04 2005-04-16 Altana Pharma Ag Combinacion sinergica que comprende roflumilast y un inhibidor de pde-3.
DE19925710C2 (de) 1999-06-07 2002-10-10 Byk Gulden Lomberg Chem Fab Neue Zubereitung und Darreichungsform enthaltend einen säurelabilen Protonenpumpenhemmer
HRP20020006A2 (en) 1999-06-07 2003-04-30 Altana Pharma Ag Novel preparation and administration form comprising an acid-labile active compound
BR0012863A (pt) 1999-08-03 2002-04-16 Lilly Icos Llc Composições farmacêuticas de "beta"-carbolina
TR200909479T2 (tr) 1999-08-21 2012-02-21 Nycomed Gmbh Sinerjistik kombinasyon.
US6174878B1 (en) 1999-08-31 2001-01-16 Alcon Laboratories, Inc. Topical use of kappa opioid agonists to treat otic pain
US6375968B1 (en) 1999-10-22 2002-04-23 3M Innovative Properties Company Encapsulated active material immobilized in hydrogel microbeads
WO2001035236A1 (en) 1999-10-25 2001-05-17 Sony Corporation Method for managing content data
HUP0203682A3 (en) 1999-10-29 2003-10-28 Smithkline Beecham Plc Method for administering a phosphodiesterase 4 inhibitor
US6258833B1 (en) 1999-12-23 2001-07-10 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6348602B1 (en) 1999-12-23 2002-02-19 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6379682B1 (en) 2000-02-07 2002-04-30 Color Access, Inc. Clear water-in-oil emulsions
US20030207845A1 (en) 2001-02-08 2003-11-06 Keating Elizabeth T. Method and compositions for treating an inflammatory disease
PL363113A1 (en) 2000-03-27 2004-11-15 Schott Glas New cosmetic, personal care, cleaning agent, and nutritional supplement compositions comprising bioactive glass and methods of making and using the same
WO2001090076A1 (en) 2000-05-25 2001-11-29 Merck Frosst Canada & Co. Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor
EP1161950A1 (en) 2000-06-09 2001-12-12 Warner-Lambert Company Use of diazepinoindoles for the treatment of chronic obstructive pulmonary disease
US20040005995A1 (en) 2001-07-26 2004-01-08 Edelson Jeffrey D Method for reducing exacerbations associated with copd
AR029984A1 (es) 2000-07-27 2003-07-23 Smithkline Beecham Corp Metodo para reducir las exacerbaciones asociadas copd ambito
EP1199074A1 (en) 2000-09-15 2002-04-24 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production
US20020193393A1 (en) 2001-03-07 2002-12-19 Michel Pairet Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
US20100310477A1 (en) 2000-11-28 2010-12-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg. Pharmaceutical compositions based on anticholingerics and additional active ingredients
DE10061137B4 (de) 2000-12-07 2016-10-06 Takeda Gmbh Neue pharmazeutische Zubereitung
UA80393C2 (uk) 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
WO2002045692A1 (en) 2000-12-07 2002-06-13 Altana Pharma Ag Pharmaceutical preparation in the form of a suspension comprising an acid-labile active ingredient
CA2430829C (en) 2000-12-07 2010-06-22 Altana Pharma Ag Rapidly disintegrating tablet comprising an acid-labile active ingredient
KR20030059314A (ko) 2000-12-07 2003-07-07 알타나 파마 아게 산 불안정성 활성 성분을 포함하는 페이스트 형태의 약학제제
NZ527585A (en) 2001-02-15 2005-04-29 Tanabe Seiyaku Co Tablets quickly disintegrated in oral cavity
MXPA03008057A (es) 2001-03-05 2004-10-15 Johnson & Johnson Composiciones farmaceuticas con sabor oculto.
FR2821745B1 (fr) 2001-03-09 2004-07-02 Ethypharm Lab Prod Ethiques Granules et granules enrobes au gout masque
US6702796B2 (en) 2001-03-26 2004-03-09 The Procter & Gamble Company Absorbent interlabial device having an improved tab
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
US6872382B1 (en) 2001-05-21 2005-03-29 Alcon, Inc. Use of selective PDE IV inhibitors to treat dry eye disorders
US20030092706A1 (en) 2001-11-09 2003-05-15 Johannes Barsig Combination
US6723348B2 (en) 2001-11-16 2004-04-20 Ethypharm Orodispersible tablets containing fexofenadine
US6756392B2 (en) 2002-02-11 2004-06-29 Pfizer Inc Nicotinamide derivatives useful as PDE4 inhibitors
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
NZ537308A (en) 2002-05-28 2009-09-25 Nycomed Gmbh Ophthalmological use of roflumilast for the treatment of diseases of the eye
US20040058950A1 (en) 2002-07-09 2004-03-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
MY151032A (en) 2002-07-19 2014-03-31 Abbott Lab S A Treatment of tnf? related disorders
US20030018071A1 (en) 2002-08-09 2003-01-23 Rennard Stephen I. Method and compositions for treating fibrotic diseases
WO2004017974A1 (en) 2002-08-10 2004-03-04 Altana Pharma Ag Piperidine-pyridazones and phthalazones as pde4 inhibitors
ES2279215T3 (es) 2002-08-29 2007-08-16 Altana Pharma Ag 2-hidroxi-6-fenilfenantridinas como inhibidores de pde-4.
WO2004022037A1 (en) 2002-09-04 2004-03-18 Ranbaxy Laboratories Limited Taste masked dosage forms and processes for their preparation
US6822114B1 (en) 2002-10-08 2004-11-23 Albemarle Corporation Process for production of fluoroalkoxy-substituted benzamides and their intermediates
UA83017C2 (uk) 2002-11-27 2008-06-10 Нікомед Гмбх Комбінація рофлуміласту та r,r-формотеролу для лікування захворювань дихальних шляхів
EP1567139B1 (en) 2002-11-27 2008-07-02 Nycomed GmbH New synergistic combination comprising roflumilast and formoterol
WO2004052345A1 (en) 2002-12-11 2004-06-24 Ranbaxy Laboratories Limited Coating composition for taste masking coating and methods for their application and use
DE602004023478D1 (de) 2003-01-30 2009-11-19 Ethypharm Sa Geschmacksmaskierte beschichtete teilchen, verfahren zur herstellung und in der mundhöhle dispergierbare tabletten enthaltend die beschichteten teilchen
KR101179012B1 (ko) 2003-03-10 2012-09-03 니코메드 게엠베하 로플루미라스트 신규한 제조 방법
US20060147382A1 (en) 2003-03-28 2006-07-06 Altana Pharma Ag Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases
EP1628682B1 (en) 2003-05-22 2013-09-25 Takeda GmbH Composition comprising a pde4 inhibitor and a pde5 inhibitor for the treatment of copd
US20050026883A1 (en) 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
WO2005013944A1 (en) 2003-08-11 2005-02-17 Merck Frosst Canada Ltd. Flavored taste-masked pharmaceutical formulation made using a one-step coating process
BRPI0413881A (pt) 2003-08-28 2006-10-24 Sandoz Ag composição farmacêutica compreendendo anticonvulsivante com revestimento de mascaramento de gosto
EP1670742A1 (en) 2003-09-12 2006-06-21 Ranbaxy Laboratories Limited Process for the preparation of roflumilast
WO2005034871A2 (en) 2003-10-09 2005-04-21 Inverseon, Inc. Methods for treating diseases and conditions with inverse agonists
BRPI0415753A (pt) 2003-10-21 2006-12-19 Pharmacia Corp método para tratamento e prevenção da inflamação respiratória com um inibidor de ciclooxigenase-2 em associação com um inibidor de fosfodiesterase 4 e composições que os contêm
US20070254928A1 (en) 2004-05-10 2007-11-01 Altana Pharma Ag Use of Roflumilast for the Prophylaxis or Treatment of Emphysema
JP2007508380A (ja) 2004-08-12 2007-04-05 シコール インコーポレイティド ３−オキシイミノステロイドの調製方法
US20060105038A1 (en) 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
WO2006094640A2 (en) 2005-03-04 2006-09-14 F.Hoffmann-La Roche Ag Roflumilast and integrin inhibitor combination and method of treatment
EP1861074B1 (en) 2005-03-16 2013-04-24 Takeda GmbH Taste masked dosage form containing roflumilast
CA2657093A1 (en) 2006-07-07 2008-01-10 Steven P. Govek Bicyclic heteroaryl inhibitors of pde4
USD580547S1 (en) 2007-07-31 2008-11-11 Nycomed Gmbh Tablet
JP2009167052A (ja) 2008-01-16 2009-07-30 Kyocera Corp 単結晶シリコン粒子の製造方法
JP5271070B2 (ja) 2008-12-24 2013-08-21 エスアイアイ・プリンテック株式会社 ヘッドチップ、液体噴射ヘッド及び液体噴射装置

Similar Documents

Publication Publication Date Title
JP2006519818A5 (enExample)
CA2503290A1 (en) Novel process for the preparation of roflumilast
CN103910672B (zh) Vismodegib的制备方法
JP2017522276A5 (enExample)
WO2015188686A1 (zh) 塞瑞替尼及其中间体的制备方法
CN1227233C (zh) 纯晶形的5－氯－3－(4－甲磺酰基苯基)－6′－甲基－[2,3′]联吡啶及其合成方法
JP2006137778A5 (enExample)
CN104557863B (zh) 一种新型烟酰胺磷酸核糖转移酶抑制剂及其合成方法与应用
JP2020508324A5 (enExample)
KR20040111490A (ko) 새로운 형태의 ｎ－（트랜스－4－이소프로필사이클로헥실카보닐）－ｄ－페닐알라닌
JP2005536559A5 (enExample)
CN101146810A (zh) 制备1-取代的1H-咪唑并[4,5-c]喹啉-4-胺化合物的方法及其中间体
CN110498771A (zh) 一种制备恶拉戈利的中间体的方法
JPWO2009028608A1 (ja) オルト位がヨウ素置換されたフェノール誘導体の製造方法
CN105085496B (zh) 一种制备拉帕替尼的方法和中间体
JP2010540440A5 (enExample)
CA2471729A1 (en) Prucalopride-n-oxide
JP7094942B2 (ja) ベンズイミダゾール誘導体の製造方法
JP2015524846A5 (enExample)
CN105085278A (zh) 一种2-甲基-1-取代苯基-2-丙胺类化合物的制备方法
JP2005501857A5 (enExample)
CN105566221A (zh) 一种稠环酰胺化合物的合成方法
CN105218477A (zh) 一种多取代苯并[b][1,4]氧氮杂卓啶衍生物及其制备方法
CN103421037B (zh) 1-乙氧羰基-5-甲基-(3r)-叔丁基二甲硅氧基戊二酸酯的合成工艺
JP2013221025A (ja) ビフェニルアセトアミド誘導体の製造方法及びその中間体